Why AstraZeneca is on investors’ radar today AstraZeneca (LSE:AZN) has been drawing attention after a period of solid share price gains. This is prompting investors to reassess how its current ...

Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

Solicitor General D. John Sauer is urging the Supreme Court to deny AstraZeneca’s petition to hear the constitutionality of ...

AstraZeneca ( ($GB:AZN) ) has issued an announcement. AstraZeneca has confirmed that, as of 31 December 2025, its issued share capital with voting ...

AstraZeneca’s ($AZN) breast cancer drug Enhertu has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA).

AstraZeneca has hailed another phase 3 win for its blood pressure drug candidate baxdrostat, boosting its attempts to turn the molecule’s long half-life into a competitive advantage. Baxdrostat, an ...

For a pharma company selling respiratory drugs, climate change would probably mean more patients and increased sales. But AstraZeneca has committed to contributing its fair share to stop that trend.

While AstraZeneca has announced that it will participate in the 2026 JP Morgan Healthcare Conference, it hasn’t yet revealed details about its presentation.

As the world went into lockdown a year ago, the workforce of AstraZeneca got news that some at the British-Swedish pharmaceutical giant considered deflating. With a global public health crisis raging ...

European pharma giant AstraZeneca Plc’s (NASDAQ:AZN) Covid vaccine, developed with the University of Oxford, is facing a class action lawsuit alleging its vaccine caused death and serious injury in ...

AstraZeneca's ambitious $80 billion revenue goal by 2030 hinges on oncology growth and successful new drug launches, but faces patent expiries and fierce competition. While current financials and ...

The participant who triggered a global shutdown of AstraZeneca’s Phase 3 Covid-19 vaccine trials was a woman in the United Kingdom who experienced neurological symptoms consistent with a rare but ...